Efficacy of a novel lumen-apposing metal stent for the treatment of symptomatic pancreatic pseudocysts
- Authors
- Song, Tae Jun; Lee, Sang Soo; Moon, Jong Ho; Choi, Hyun Jong; Cho, Chang Min; Lee, Kwang Hyuck; Park, Se Woo; Kim, Seong-Hun; Lee, Seung Ok; Lee, Yun Nah; Lee, Jong Kyun
- Issue Date
- Sep-2019
- Publisher
- Mosby Inc.
- Keywords
- Efficacy of a novel lumen-apposing metal stent for the treatment of symptomatic pancreatic pseudocysts
- Citation
- Gastrointestinal Endoscopy, v.90, no.3, pp 507 - 513
- Pages
- 7
- Journal Title
- Gastrointestinal Endoscopy
- Volume
- 90
- Number
- 3
- Start Page
- 507
- End Page
- 513
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4283
- DOI
- 10.1016/j.gie.2019.05.033
- ISSN
- 0016-5107
1097-6779
- Abstract
- Background and Aims: Recently, a newly designed lumen-apposing metal stent (LAMS) with a conventional delivery system was developed. The purpose of this study was to evaluate the effectiveness and safety of a newly designed LAMS for EUS-guided drainage to treat symptomatic pancreatic pseudocysts. Methods: This prospective multicenter cohort study included 34 patients with symptomatic pancreatic pseudocysts from 2016 to 2017. The patients underwent EUS-guided drainage with the newly designed LAMS (Niti-S SPAXUS; Taewoong Medical Co, Ltd, Ilsan, South Korea). Effectiveness outcome measurements included technical success rate, clinical success rate, successful stent removal rate, and procedural time. Safety outcome measurements included procedure and/or stent-related adverse events (AEs) and overall AEs. Patients were prospectively followed, and consecutive data were collected at discharge, at stent removal, and 20 days after stent removal. Results: Thirty-four patients (mean age 51.7 +/- 13.3 years, 26 men) were enrolled. The mean pseudocyst size was 9.23 +/- 3.54 cm. The technical success rate was 97.1% (33/34). The clinical success rate was 94.1% (32/34). All stents were successfully removed. The mean procedural time from needle puncture to stent deployment was 10.3 +/- 5.7 minutes. Four patients (11.8%) experienced procedure and/or stent-related AEs, including stent maldeployment (n = 1) and pseudocyst infection (n = 3). All patients completely recovered from the AEs. Bleeding caused by the stent or buried LAMS syndrome was not observed. No unplanned endoscopic procedures were required. Conclusions: This study showed that EUS-guided drainage using the newly designed LAMS is technically feasible and effective for the treatment of symptomatic pancreatic pseudocysts.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4283)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.